It has been pointed out that a financial management plan needs to be established for high-priced drugs listed through the general system, as well as a system to evaluate and manage the performance of high-priced drugs that were granted reimbursement through the risk-sharing agreement (RSA) scheme in order to manage the soundness of the National Health Insurance drug finances.

In other words, the criticism was that health authorities need to devise multifaceted drug price negotiation models to manage health insurance finances spent on high-priced drugs listed through the general process as no other mechanism than the one that reduces a drug’s price upon patent expiry exists in the current state.